Deana Ferreri, PhD

Chronic kidney disease complicates cancer treatment, leading to reduced chemotherapy use. Personalized approaches are essential for optimal patient outcomes.

Experts advocate for a shift in CKD care towards prevention and maintaining kidney health, emphasizing lifestyle changes and early interventions.

Explore safe IBD treatment options for patients with chronic kidney disease, focusing on tailored approaches to optimize kidney health and medication efficacy.

Recent studies highlight ustekinumab's effectiveness and safety in treating Crohn disease, especially for patients unresponsive to prior therapies.

A low-protein diet is essential for managing chronic kidney disease (CKD), potentially slowing progression and improving health outcomes while tailoring to individual needs.

Explore the evolving landscape of biologics in metabolic syndrome treatment, highlighting GLP-1 analogs and PCSK9 inhibitors for improved patient outcomes.

A study reveals real-world effects of switching to adalimumab biosimilar Hyrimoz, highlighting flare rates and injection pain concerns in inflammatory disease patients.

A study reveals high drug survival rates for anti-TNF biosimilars in treating psoriasis and psoriatic arthritis, highlighting their long-term efficacy and safety.

SB17, a new ustekinumab biosimilar, demonstrates comparable efficacy and safety for psoriasis and psoriatic arthritis, enhancing patient experience and convenience.

Using vedolizumab first, before tumor necrosis factor-α inhibitors, improved quality-adjusted life-years in both ulcerative colitis and Crohn disease, and was less costly in ulcerative colitis, according to a real-world economic analysis from the EVOLVE study.

Functional similarity of the ustekinumab biosimilar ABP 654 (Wezlana) and the reference product (Stelara) was confirmed by a series of in vitro studies, which support the totality of evidence for the biosimilar's FDA approval.

Switching back from infliximab biosimilar SB2 to reference infliximab (Remicade) did not affect clinical disease activity or safety in inflammatory bowel disease (IBD), according to a prospective cohort study.

A real-world study in France found patient satisfaction was stable after switching from either the reference product or a low-concentration adalimumab biosimilar to the adalimumab biosimilar CT-P17, a high-concentration, citrate-free formulation.

Increasing knowledge of mutations and signaling proteins in diffuse large B-cell lymphoma (DLBCL) offer prognostic and therapeutic advantages, according to a review of recent findings.

Special approval programs have increased FDA administrative costs (paid for mostly by user fees), and postponements of generic competition have been costly to the US healthcare system, according to a recent article in JAMA.